The Inhibitor of Cyclin-Dependent Kinases, Olomoucine II, Exhibits Potent Antiviral Properties

Background: Olomoucine II, the most recent derivative of roscovitine, is an exceptionally potent pharmacological inhibitor of cyclin-dependent kinase activities. Here, we report that olomoucine II is also an effective antiviral agent. Methods: Antiviral activities of olomoucine II were tested on a range of human viruses in in vitro assays that evaluated viral growth and replication. Results: Olomoucine II inhibited replication of a broad range of wild-type human viruses, including herpes simplex virus, human adenovirus type-4 and human cytomegalovirus. Olomoucine II also inhibited replication of vaccinia virus and herpes simplex virus mutants resistant to conventional acyclovir treatment. This report is the first demonstration of a poxvirus being sensitive to a cyclin-dependent kinase inhibitor. The antiviral effects of olomoucine II could be observed at lower concentrations than with roscovitine, although both were short-term. A remarkable observation was that olomoucine II, when used in combination with the DNA polymerase inhibitor cidofovir, was able to almost completely eliminate the spread of infectious adenovirus type-4 progeny from infected cells. Conclusions: Our results show that when targeting two complementary antiviral mechanisms, strongly additive effects could be observed.

[1]  B. Ahn,et al.  Vaccinia virus‐mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP , 2008, Cellular microbiology.

[2]  A. J. Kapasi,et al.  Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome , 2007, Journal of Virology.

[3]  L. Schang,et al.  Five Years of Progress on Cyclin-Dependent Kinases and other Cellular Proteins as Potential Targets for Antiviral Drugs , 2006, Antiviral chemistry & chemotherapy.

[4]  H. Klenk,et al.  Virology Journal BioMed Central Methodology , 2006 .

[5]  M. Walkinshaw,et al.  Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor , 2005, Cellular and Molecular Life Sciences CMLS.

[6]  G. Wilkinson,et al.  Characterization and manipulation of the human adenovirus 4 genome. , 2004, The Journal of general virology.

[7]  L. Schang,et al.  Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors , 2004, Journal of Virology.

[8]  A. Kudoh,et al.  Inhibition of S-Phase Cyclin-Dependent Kinase Activity Blocks Expression of Epstein-Barr Virus Immediate-Early and Early Genes, Preventing Viral Lytic Replication , 2004, Journal of Virology.

[9]  P. Tomasec,et al.  The most abundantly transcribed human cytomegalovirus gene (beta 2.7) is non-essential for growth in vitro. , 2003, The Journal of general virology.

[10]  L. Meijer,et al.  Cyclin dependent kinase inhibitors , 2003 .

[11]  H. Einsele,et al.  Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation , 2003, Bone Marrow Transplantation.

[12]  T. Walls,et al.  Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. , 2003, The Lancet. Infectious diseases.

[13]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[14]  M. Strnad,et al.  Synthesis and biological activity of olomoucine II. , 2002, Bioorganic & medicinal chemistry letters.

[15]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[16]  F. Kashanchi,et al.  Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors , 2002, Molecular and Cellular Biochemistry.

[17]  L. Meijer,et al.  Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins , 2002, Journal of Virology.

[18]  J. Karn,et al.  Phosphorylation of the RNA Polymerase II Carboxyl-Terminal Domain by CDK9 Is Directly Responsible for Human Immunodeficiency Virus Type 1 Tat-Activated Transcriptional Elongation , 2002, Molecular and Cellular Biology.

[19]  A. Giordano,et al.  Physical interaction between pRb and cdk9/cyclinT2 complex , 2002, Oncogene.

[20]  P. Schaffer,et al.  The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits the Transactivating Activity and Alters the Posttranslational Modification of Herpes Simplex Virus Type 1 ICP0 , 2002, Journal of Virology.

[21]  Tamás Kiss,et al.  7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes , 2001, Nature.

[22]  M. Ljungman,et al.  The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. , 2001, Molecular pharmacology.

[23]  L. Meijer,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors , 2001, Journal of Virology.

[24]  N. Kapoor,et al.  Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  A. Murray,et al.  Can sequencing shed light on cell cycling? , 2001, Nature.

[26]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[27]  A H Calvert,et al.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.

[28]  J. Buolamwini.  Cell cycle molecular targets in novel anticancer drug discovery. , 2000, Current pharmaceutical design.

[29]  P. Schaffer,et al.  Transcription of Herpes Simplex Virus Immediate-Early and Early Genes Is Inhibited by Roscovitine, an Inhibitor Specific for Cellular Cyclin-Dependent Kinases , 1999, Journal of Virology.

[30]  P. Schaffer,et al.  Requirement for Cellular Cyclin-Dependent Kinases in Herpes Simplex Virus Replication and Transcription , 1998, Journal of Virology.

[31]  Mahitosh Mandal,et al.  Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK) , 1998, Oncogene.

[32]  D. Hazuda,et al.  P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. , 1997, Genes & development.

[33]  P. Chi,et al.  Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. , 1997, Virology.

[34]  L. Meijer,et al.  Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.

[35]  D. Grandér,et al.  Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines , 1997, Oncogene.

[36]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[37]  M. J. Nicholl,et al.  Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific , 1996, Journal of virology.

[38]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[39]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[40]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[41]  L. Tsai,et al.  A family of human cdc2‐related protein kinases. , 1992, The EMBO journal.

[42]  B. Moss,et al.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes , 1987, The Journal of experimental medicine.

[43]  G. McFadden,et al.  Biogenesis of poxviruses: role for the DNA-dependent RNA polymerase II of the host during expression of late functions. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Santamaría,et al.  Cyclins and CDKS in development and cancer: lessons from genetically modified mice. , 2006, Frontiers in bioscience : a journal and virtual library.

[45]  A. Senderowicz,et al.  Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials , 2004, Investigational New Drugs.

[46]  M. Ljungman,et al.  The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. , 2001, Molecular pharmacology.

[47]  P. Schaffer,et al.  Modification of Herpes Simplex Virus Type Activity and Alters the Posttranslational Roscovitine Inhibits the Transactivating the Cyclin-dependent Kinase Inhibitor , 2022 .

[48]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[49]  里本 一剛.  Cyclin A and Cdk2 kinase activity are suppressed by combined treatment with tumor necrosis factor-α and interferon-α , 1996 .

[50]  M. J. Nicholl,et al.  Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific , 1996, Journal of virology.